BioCentury
ARTICLE | Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

June 20, 2018 1:53 AM UTC

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of the knee. Cingal comprises a single injection of sodium hyaluronate with triamcinolone hexacetonide.

The primary endpoint of the 576-patient 16-02 trial evaluated Cingal compared with triamcinolone hexacetonide alone in the change from baseline in knee pain as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at week 26. Anika did not disclose detailed data, but said the reduction in pain and overall symptom relief with Cingal were consistent with results from the placebo-controlled Phase III 13-01 trial of the product in the indication...